Patients who were being treated with anti‐CD20 agents reported the greatest overall satisfaction regarding control of their ITP (79%; n = 55/70), with similar results for thrombopoietin receptor agonists (76%; n = 182/240), intravenous immunoglobulin (69%; n = 77/112), but less positive results for corticosteroids (53%; n = 194/368). The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.